First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

BACKGROUND: In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after infusion of a humanized monoclonal antibody to amyloid β, AAB-003 (NCT01193608; re...

Full description

Saved in:
Bibliographic Details
Published in:Alzheimers Res Ther
Main Authors: Delnomdedieu, Marielle, Duvvuri, Sridhar, Li, David Jianjun, Atassi, Nazem, Lu, Ming, Brashear, H. Robert, Liu, Enchi, Ness, Seth, Kupiec, James W.
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4772335/
https://ncbi.nlm.nih.gov/pubmed/26925577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-016-0177-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items